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Abstract
Trypanosoma cruzi is a remarkably versatile parasite. It can parasitize almost any nucleated cell type  and 
naturally infects hundreds of mammal species across much of the Americas. In humans it is the cause of 
Chagas disease, a set of mainly chronic conditions predominantly affecting the heart and gastrointestinal 
tract that can progress to become life threatening. Yet around two thirds of infected people are long-term 
asymptomatic carriers. Clinical outcomes depend on many factors, but the central determinant is the 
nature of the host-parasite interactions that play out over the years of chronic infection in diverse tissue 
environments.  In this review, we aim to integrate recent developments in the understanding of the 
spatial and temporal dynamics of T. cruzi infections with established and emerging concepts in host 
immune responses in the corresponding phases and tissues. 
Trypanosoma cruzi: A Formidable Foe
Trypanosoma cruzi, the causative agent of Chagas disease (American trypanosomiasis), is an 
extraordinarily versatile parasite. Its wild transmission cycles across the Americas are maintained by over 
100 species of haematophagous triatomine bugs. Chagas disease is a zoonosis and T. cruzi infects diverse 
mammal reservoir species, including marsupials, bats, rodents, ungulates, carnivores (including domestic 
cats and dogs), armadillos, pilosans and primates (1). T. cruzi undergoes regulated morphological 
transitions involving at least four developmental forms, each with a distinctive biology e.g. cell structural 
features, modes of motility, surface protein coats (2) and metabolic programmes (3). The epimastigote 
form replicates in the vectors gut, then differentiates to a highly motile form, the metacyclic 
trypomastigote, which invades mammalian host cells after transmission. Potentially any nucleated cell 
type may be parasitized in any tissue the trypomastigote can reach (4-16). After invasion and escape from 
a parasitophorous vacuole into the cytosol, another transition occurs to the amastigote form, which 
replicates repeatedly and then differentiates to generate a population of pleomorphic tissue/bloodsteam 
form trypomastigotes. These are released into the extracellular space from where they may infect a new 
cell, in some cases after migration to the bloodstream. Alternatively, in the rare event they are taken up in 
a triatomine blood meal, they can complete the cycle by differentiating into epimastigotes.
Mounting evidence shows T. cruzis life cycle is considerably more complex than the textbook view. 
Findings include epimastigote-like forms in mammals, asynchronous replication and trypomastigogenesis, A
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asymmetric divisions, reversible transitions and formation of apparently quiescent or dormant 
amastigotes (17-22). The morphological, antigenic and spatial variability, combined with active evasion 
strategies presents a formidable challenge to the mammalian immune system. Nevertheless, most 
infections resolve to a stable chronic equilibrium of parasite replication and suppression via a combination 
of sustained antibody and type 1 cellular responses. The majority of people (>95%) survive acute infection 
and progress to a chronic, asymptomatic phase. Chagas cardiomyopathy is then estimated to develop at a 
rate of ~2% per year (23). Disorders of the gastrointestinal (GI) tract develop in a smaller proportion of 
cases, sometimes in combination with cardiac disease (24). Why Chagas pathology only affects a limited 
subset of tissues in only a specific subset of infected people is one of the longest-standing and most 
important unanswered questions in the field. 
In this review, our aim is to integrate recent developments in the understanding of the spatial and 
temporal dynamics of T. cruzi infections with established and emerging concepts in host immune 
responses in the corresponding phases and tissues. The result is a view that parasite persistence occurs in 
a small number of privileged tissues alongside highly competent, T. cruzi-specific systemic responses, 
suggesting a substantial degree of compartmentalization, even within tissues. The low-level, yet perpetual 
chronic inflammation has the potential to become pathological, dependent on largely undefined host, 
parasite and environmental factors. Thus, progress in the development of anti-parasitic drugs, adjunct 
treatments, immunotherapies and vaccines is likely to require a much better understanding of the 
molecular and cellular determinants of T. cruzi persistence at the tissue-specific and even hyper-local, 
intra-tissue scale.
Advances in studies of tissue-specific infection dynamics
While T. cruzi must spend some time in extracellular environments of the blood and interstitial fluid to 
sustain infections and ensure transmission, it is predominantly an intracellular parasite of solid organs. 
Consequently, most of what is known of the cells and tissues targeted by T. cruzi comes from 
experimental animal studies. It is difficult to obtain robust data on tissue distribution in human patients, 
although post-mortem, transplant and biopsy results tend to be consistent with animal models. The 
mouse is the species of choice, but other rodents, rabbits, dogs and non-human primates have also 
demonstrated utility (25). Tissue-specific parasite loads can be measured by a range of direct and indirect 
methods (reviewed in (26). Developments in real-time bioluminescence imaging methods have 
underpinned much recent progress in understanding T. cruzi infection dynamics (4, 5, 27-31). These A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved
systems are based on transgenic parasites expressing luciferases, enabling analysis of light signals emitted 
by parasites in discrete anatomical locations. Major advantages include greatly reduced tissue sampling 
bias and the ability to monitor individual mice over time. Bioluminescence lacks the resolution necessary 
to visualise parasites at individual cell scale, but this can be achieved using parasites expressing 
fluorescent reporters (21, 32, 33), an approach that becomes particularly powerful when luciferase-
fluorescence fusion proteins are employed (22, 34) (Figure 1). The possibility to integrate these imaging 
methods with analyses of concomitant immune responses (35) holds considerable promise for advancing 
our understanding of T. cruzi  host interactions. 
Stage 1: T. cruzi systemic colonisation and innate responses
In vectorial transmission scenarios, infection results from contamination of the triatomine bite wound or 
of mucosal membranes with trypomastigotes present in the bugs faeces. Transmission may also occur 
orally, via contaminated food or drink, in utero, and by blood transfusion and organ transplant. Several 
mechanisms of host cell invasion have been described and reviewed elsewhere (36). In humans, oedema 
with intense mononuclear infiltrate at the entry site in the skin (chagoma) or eye (Romañas sign) indicate 
an initially very localised infection (37). However, the true extent of trypomastigote dissemination is not 
clear and surprisingly little is known at the cellular level about the actual sites of primary invasion and the 
first cycle of intracellular parasite replication, which lasts approximately one week. Experimental animal 
studies indicate that the route of inoculation is a key factor. Intra-peritoneal injection results in similar 
parasite numbers in diverse tissues after six days (38). Conversely, oral transmission results in highly 
localised infections in the stomach or nasomaxillary tissues (31, 38, 39) with initial infection of the local 
mucosal epithelium (40). Similarly, after conjunctival inoculation, parasites first invaded and replicated in 
the mucosal epithelium of the nasolacrimal ducts and nasal cavities (41). 
At the end of the first intracellular cycle, trypomastigotes are released and the infection disseminates 
widely. T. cruzi is pan-tropic in the acute phase of infection (reviewed in (26). However, the relative 
intensity of infection in different cell or tissue types again varies depending on the inoculation route, 
inoculum size as well as intrinsic factors such as replication rate and capacity for dissemination. Sites 
reported to harbour the highest acute infection intensities include skeletal, smooth and cardiac muscle 
and adipose tissues. Some studies have described T. cruzi strains with an increased capacity to parasitize 
mononuclear phagocytes (13, 42, 43) or to cross the blood-brain barrier (12, 44, 45). 
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Sensors
The host response to T. cruzi primary infection is considered to be markedly delayed by comparison with 
model intra-cytosolic pathogens (46, 47). The main features of the immediate response are the induction 
of type I interferon signalling and recruitment of neutrophils, macrophages and Natural Killer (NK) cells 
(48). Ca2+ mobilization, associated with invasion of myeloid cells, can activate the transcription factor 
NFATc1, leading to interferon gamma 7:J production by NK cells and dendritic cell (DC) maturation 
(49). T. cruzi also produces multiple B cell mitogens that directly trigger a robust T-independent B cell 
activation (50-52).
Few canonical pathogen associated molecular patterns (PAMPs) are conserved in T. cruzi. The best 
characterised innate pattern recognition receptors (PRRs) for T. cruzi PAMPS are Toll-like receptor (TLR) 2 
and 9. These recognise, respectively, the glycophosphatidylinositol (GPI) anchor of parasite surface 
proteins and parasite genomic DNA, specifically unmethylated CpG motifs (53, 54). TLR2+9 double 
knockout mutant mice suffer higher, parasitaemias and significantly increased mortality rates (50% by day 
50) compared to wild type controls (54). Mice lacking both MyD88 and TRIF, thus rendered incapable of 
any TLR-mediated responses, have uncontrolled parasitaemia and 100% mortality by 18 days of infection 
(55). This may be explained by the additional involvement of TLR4 and TLR7, recognising parasite 
glycoinositolphospholipids and RNA respectively (56-58).
Many T. cruzi surface proteins are extensively glycosylated (2) and several host galectins (a widely 
expressed family of carbohydrate-binding proteins) are able to bind them (59). Interactions involving 
several different galectins may actually help T. cruzi bind to and enter host tissues (60, 61), but this does 
not appear to directly trigger any anti-parasitic effector activity. As an occupant of the host cell cytoplasm, 
it is likely that T. cruzi triggers cytosolic sensors. The best known candidate systems centre on NOD-like 
receptors (NLR). Mice lacking the NOD1 receptor suffer 100% mortality to acute T. cruzi infection, 
although the mechanism explaining this remains obscure (62). Studies also support a parasite-suppressive 
role for the related receptor, NLRP3 and downstream components of the inflammasome complex that 
drives 
K and IL-18 secretion (63-65), although as with NOD1 it is not clear if this involves direct sensing 
of T. cruzi in vivo. 
The majority of studies of innate immunity to T. cruzi have focussed on responses in myeloid cells, 
especially macrophages, yet these could represent only a minor subset of the parasites early targets. A
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Transcriptomic analysis of in vitro infected human fibroblasts revealed that inflammatory cytokine 
expression peaked 24 hr post-infection and the TLR-independent type I IFN response became the 
dominant signature by 72 hrs, which was suggested to promote, rather than inhibit, the infection (66). 
Trypomastigotes have a diverse secretome comprising proteins in native form and also as cargoes in shed 
extracellular vesicles (67-70). Important research questions to address include whether and at what point 
these are relevant for triggering PRRs in vivo and whether there are equivalent processes for intracellular 
amastigotes.
After the first cycle of replication ends, host cells rupture and trypomastigotes escape into the 
extracellular environment. At this point, trypomastigotes may invade local tissue cells, enter infiltrating 
leukocytes or migrate via the blood or lymphatics to other tissues. The factors governing the parasites 
propensity to stay local or not remain obscure. Host cell rupture releases intracellular material rich in 
danger associated molecular patterns (DAMPs), further stimulating innate signalling via TLRs as well as, 
for example, degranulation of nearby mast cells and activation of myeloid cells. Recently, sensing of 
oxidised DNA in extracellular vesicles via cyclic GMP-AMP Synthase (cGAS) was identified as an important 
DAMP recognition mechanism for macrophage activation (71). As a eukaryote, T. cruzi has endogenous 
orthologues of many mammalian DAMPS, potentially blurring the boundaries between DAMPs and 
PAMPs. For example, recombinant T. cruzi High Mobility Group B (TcHMGB) protein can induce 
production of nitric oxide (NO) in macrophages in vitro and expression of genes encoding inflammatory 
cytokine genes in vivo (72). 
Signal Mediators and Amplifiers
A plethora of cross-talking signalling pathways are activated downstream of the PAMP/DAMP sensors 
described above. Signalling converges on a set of transcription factors, (NF-K2 AP-1, IRF3) which results in 
production of inflammatory cytokines (73-76). Critical amongst these are the IL-12 family, 7:J and 8:7L2 
the canonical drivers of type 1 immune responses required to tackle intracellular infections. IL-12 is 
essential for the early activation of recruited natural killer cells and their production of 7:JM both these 
cytokines are indispensable for control of parasite loads and avoidance of acute mortality (77). 8:7L is 
also essential for survival of the acute stage (78). IFNy and 8:7L activate parasite destructive effector 
mechanisms via autocrine and paracrine signalling. Beyond the canonical 
7:J axis, signalling 
through the IL-1 receptor is essential for early (10 days p.i.) induction of myocarditis needed to control 
heart parasitism (65). A
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The local tissue response is amplified via chemokine-driven recruitment of inflammatory monocytes, 
macrophages, neutrophils and, eventually, antigen (Ag) specific CD4+ helper T and CD8+ cytotoxic T 
lymphocytes (Th and CTL) to the site of infection (79). Microvascular plasma leakage into parasitized 
tissues is promoted further by activation of mast cells and the kallikrein-kinin system (KKS), via a 
mechanism involving cruzipain, a parasite-derived cysteine protease (80). The resulting tissue oedema 
and upregulation of associated receptors on cardiomyocytes may increase specific susceptibility to heart 
invasion as the infection progresses (81). 
Innate effectors and their evasion
The infection, cell necrosis and associated inflammatory signalling result in the activation of a range of 
innate effector mechanisms. There is some evidence from analysis of Beclin-1-deficient mice that host cell 
autophagy can provide some marginal early restraint on parasite replication (82). Epimastigotes are 
complement-sensitive but trypomastigotes have effective molecular mechanisms providing resistance to 
complement-mediated lysis (83). Infiltrating NK cells, in addition to being major producers of 7:J2 may 
have direct parasiticidal effects involving release of cytotoxic granules (84). 
An unusual population of innate-like CD8+ T cells with activation characteristics of (e.g. production of 
granzyme A and 7:J expands in the thymus of T. cruzi-infected mice. These cells appear to be driven by 
antigen-independent mechanisms and adoptive transfer experiments of thymocytes from infected mice 
suggest they might provide protection from otherwise lethal challenge (85); however, the underlying 
mechanisms conferring this protection remain to be elucidated.
Reactive oxygen and nitrogen species (ROS, RNS) are principal effectors for T. cruzi control. These are 
generated by 7:JA8:7L,',  macrophages and via diverse other mechanisms in non-phagocytes 
and extracellular compartments (86). They are a significant cause of collateral damage in infected tissues, 
but high levels are necessary because T. cruzi has an extensive and highly effective anti-oxidant defence 
system (86, 87). ROS can even promote T. cruzi replication, by a mechanism proposed to depend on the 
increased availability of intracellular Fe2+ ions that the parasite can utilise (88). Nitric oxide (NO) is directly 
parasiticidal in vitro (89) and inducible NO synthase (iNOS) is essential for in vivo parasite control in some 
models (62, 77, 90), although not in others (63, 91). 
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Despite the plethora of innate responses, the overall effectiveness of T. cruzis evasion mechanisms 
renders it debatable whether they actually have any meaningful impact on most infections apart from the 
induction and conditioning of the adaptive response (see below). Indeed, T. cruzi infections are 100% 
lethal in mice that are genetically incapable of mounting adaptive responses (SCID, RAG, nude) (92-94) 
and bioluminescence imaging studies show that parasite growth in such mice is close to exponential (4). 
Stage 2: Adaptive responses take control
The infection usually peaks, in terms of total parasite numbers and the extent of tissue dissemination, at a 
point between 2 and 3 weeks post-infection. Over the following weeks, parasite loads are reduced by 
several orders of magnitude by a highly adaptive immune response. Although they are ultimately thought 
to be non-sterilizing in virtually all cases (95), it is worth reviewing the key features at the systemic level 
before we consider the tissue-specific host-parasite dynamics at play in the chronic phase. We also refer 
readers to more in-depth reviews of adaptive immunity in Chagas disease (46, 96, 97). 
T and B cell activation
T. cruzi cycles between the cytosolic and extracellular compartments and, accordingly, its control is 
critically dependent on the generation and deployment of Ag-specific CTL to infected tissues and antibody 
production by B cells. This is evidenced by relevant gene disruption and antibody-mediated depletion 
experiments in mice (98-102). Mature DCs in the spleen and lymph nodes draining infected tissues, 
conditioned by the inflammatory environment, activate parasite Ag-specific CD8+ and CD4+ T cells from 
the naïve pools (47, 103). Activated T cells then migrate to sites of infection to exert effector mechanisms 
or in some cases begin differentiation to memory subsets (102, 104). A number of factors may impinge on 
the quality and magnitude of the T cell response, including parasite-driven immature thymocyte apoptosis 
(105) and direct and indirect modulation of DC-T cell interactions (106-109). In terms of antigen 
specificity, the murine T cell repertoire is focussed mainly on a small number of immunodominant 
epitopes from highly expressed surface proteins (110-112) but in humans there is evidence of a broader 
hierarchy (97, 113) and immunodominance appears not to directly contribute to chronicity. 
The role of CD4+ T cells is not well characterised, but the association between HIV infection and life-
threatening acute T. cruzi relapse in humans (114) indicates they are critical for parasite control. 
Accordingly, mice that are specifically incapable of mounting CD4+ T cell responses experience 100% acute A
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lethality of T. cruzi infection (115). This has been linked to loss of support for parasite-specific CD8+ T cell 
cytotoxicity against i.v. delivered splenocytes loaded with parasite antigens from the ASP-2 gene (99), but 
not in similar experiments using trans-sialidase peptides (116). This may reflect differing requirements for 
T cell help depending on immunodominance hierarchies (97). Nevertheless, the majority of CD4+ T cells 
develop a protective Th1 profile and contribute further to the abundance of type 1 cytokines, particularly 
7:J (93, 117-119). Broader phenotypic diversity does develop alongside Th1 predominance, including 
minor Th17, Th1/Th17 intermediate and possibly Th2 subsets in some circumstances (118, 120-124). 
There is no clear consensus on the relevance of these to parasite control and immunopathogenesis, but 
this is an active area of research. The CD4+ T cells that provide B cell help are termed follicular helper T 
cells (Tfh), and represent a distinct CD4+ T cell programme regulated by the master transcription factor 
Bcl6. Although activation of Tfh responses to T. cruzi infection has not been explored in detail, it is 
reasonable to hypothesize that they are required for the production of T. cruzi-specific antibodies and 
ultimate control of the infection. In line with this, IL-6, which supports Tfh differentiation (125, 126), is 
required for the control of parasitaemia and splenocyte recall response to parasite antigens (127), but not 
for T-cell independent polyclonal activation of B cell responses (51). 
The initial B cell response in the spleen is estimated to be at least 10-fold higher as compared to LNs 
draining infected tissues (52) and a robust T. cruzi-specific antibody response is still generated there 
alongside the aforementioned polyclonal B cell activation and non-specific hyper-gammaglobulinaemia. 
The parasite-specific antibody response is presumably driven by B cell activation involving T cell 
collaboration because it is accompanied by a robust germinal centre B cell response and production of 
parasite-specific class-switched antibodies (52). The specific and non-specific splenic B cell responses 
appear to be either differentially regulated or carried out by different B cell compartments because only 
the latter depend on the cytokine B cell activating factor (BAFF) (128). 
Activation of auto-reactive T and B cell clones, the latter leading to the production of autoantibodies, are 
well described phenomena during T. cruzi infection (129). Polyclonal B cell activation, host molecular 
mimicry by parasite proteins and bystander activation caused by tissue damage have been postulated as 
underlying mechanisms (129). There is broad evidence and consensus that parasite persistence is required 
to sustain these autoimmune responses (130-132). Nevertheless, the significance of autoantibodies and 
auto-reactive T cells for Chagas disease pathogenesis and the mechanisms involved in their production 
during T. cruzi infection remain major unresolved questions.
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It has been suggested that the non-specific polyclonal B cell activation contributes to delay the generation 
of T. cruzi-specific B cell responses, thus contributing to parasite escape and establishment of chronic 
infections (133, 134). Polyclonal B cell activation is associated with rapid, innate-like production of IL-17 
and IL-10 (135, 136) but the wider relevance is unclear as both protective (136-138) and deleterious (51, 
52, 135) roles for such innate-like B cell responses have been documented in different models. The 
infection also causes a transient, yet marked loss of immature B cells in the bone marrow in experimental 
mouse models, possibly further compromising the response (139).
The kinetics of the adaptive response depend to some extent on the early parasite load (99) but in most 
cases it coincides with second or third intracellular cycle and is considered relatively delayed (47). 
Nevertheless, substantial immune memory can be generated quite rapidly: mice whose infections were 
cured by benznidazole anti-parasitic chemotherapy starting 4 or 14 days after infection were then able to 
restrict acute parasite loads in challenge infections by 85% and >99% respectively (35). Notably though, 
very few of these animals achieved sterile cure and they progressed to chronic phase infections that were 
comparable to primary infections in naïve mice. This raises important questions about what is mediating 
memory responses to secondary infections, for example whether they are T cell-dependent or 
independent. 
Adaptive effector mechanisms
Lymphocytes contribute to control of T. cruzi by production of type 1 cytokines that amplify the prior, 
innate ROS and RNS production in infected tissues. Their signature, direct effector mechanisms are also 
crucial. These include the principal CTL effector pathways, namely perforin-mediated delivery of 
granzymes and FasL-induced apoptosis. In particular, granzymes cause fatal oxidative damage to T. cruzi, 
which can be mitigated by ROS scavenging drugs or overexpression of parasite antioxidant genes (140). 
This may potentially be accelerated in humans by granulysin-mediated delivery of granzymes directly into 
intracellular parasites themselves (140). Mice do not have a granulysin gene but in most cases still achieve 
good control of parasite levels, so immune pressure may be more focussed on extracellular amastigotes 
after host cell apoptosis and on clearance of trypomastigotes. These canonical pathways are essential in 
some experimental models (140-142) but dispensible in others (98, 143). The difference is likely explained 
by other pathways providing sufficient compensatory effector capacity in lower parasite load or virulence 
scenarios. 
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T. cruzi-specific lytic and neutralizing antibodies are normally detected in humans and animal models 
(144-147). These are mostly produced in the spleen; antibody secretion by bone marrow cells obtained 
from acutely infected mice is below detection level (52). This suggests that either plasma cells generated 
in secondary lymphoid organs during acute T. cruzi infection are unable to migrate to the bone marrow, 
or that the bone marrow may not sustain plasma cell survival during the early phase of the infection, or 
that plasma cell homing in the bone marrow is somehow delayed during T. cruzi infection. Whether this is 
a temporary mechanism or extends throughout chronic infection, and whether it is a direct mechanism 
driven by presence of the parasite in the bone marrow, are unknown. 
Antibodies target extracellular trypomastigotes but they may also have a role in binding amastigotes 
released from ruptured host cells, for example, downstream of CTL-mediated lysis. Opsonized parasites 
are efficiently taken up by tissue-resident macrophages, especially in highly-vascularised organs e.g. liver, 
lung, spleen (148, 149). It is not clear how a subset of trypomastigotes evade this fate to sustain chronic 
infections. Beyond their role as antibody producers, B cells are critically required for functional T cell 
responses to control T. cruzi infection (102, 150-152) and production of cytokines including IL-17 and IL-10 
(135, 136). 
Deactivating / Regulatory Mechanisms
The strong and sustained systemic inflammation, host cell lysis and tissue parasite killing in this control 
phase causes potentially dangerous levels of collateral tissue damage. Infections may become overtly 
symptomatic and in some cases fatal, particularly if the CNS is involved (153). Tissue-protective immune 
regulatory pathways are therefore initiated to dampen the inflammatory response, to the benefit of the 
remaining parasites, which form the founding populations of the chronic infection reservoirs (Figure 3). 
The factor with the strongest evidence for an important regulatory role is probably the cytokine IL-10. 
Early studies of IL-10 deficiency using high virulence Tulahuen strain parasites reported better control of 
acute T. cruzi parasitaemia at the expense of rapidly fatal (~2 weeks p.i.) pathogenic inflammation e.g. 
8:7L$ ,  toxic shock (154, 155). More recent studies point to additional complexity. Rôffe et al 
(2012) reported IL-10 was essential to protect against later mortality (3-6 weeks p.i.) associated with poor 
control of Colombiana strain tissue parasite loads and increased myocarditis intensity. In still lower 
virulence scenarios, the absence of IL-10 has been associated with reduced CTL effector function but 
without any increased mortality (156). Both CD8+ and CD4+ T cells are IL-10 sources and a high proportion A
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simultaneously produce 7:J (157), likely supported by IL-27 production (158) and potentially in direct 
response to parasite shed trans-sialidase (123). B cells also produce IL-10 (135) and overall IL-10 
production is lower in B1 B cell-deficient mice early during infection (159). CD11b+ B1 B cells from 
asymptomatic, infected individuals show increased capacity to produce IL-10 compared to those with 
cardiac disease symptoms (138). In addition, recent data shows that when compared to non-infected 
donors, chronically T. cruzi-infected individuals with cardiac manifestations have an increased proportion 
of immature transitional CD24highCD38high and naïve B cells able to produce IL-10 upon in vitro re-
stimulation (160). This suggests B cell-intrinsic IL-10 signalling might be important to regulate the intense 
adaptive immune response, as is the case for other parasitic infections (161), but direct mechanistic 
evidence is required to support this hypothesis. 
Transforming growth factor beta (8F7K), another potent regulatory and tissue protective cytokine, can 
be activated from its latent form by a T. cruzi protease (cruzipain) in vitro (162). 8F7K signalling to T cells 
reduces the risk of late acute mortality and this appears to involve inhibition of cell proliferation rather 
than suppression of inflammatory cytokine production (106, 163). Other factors potentially contributing 
to early inhibition of adaptive immune effector responses include suppressor of cytokine signalling (SOCS) 
(164), regulatory CD4+ T cells (Tregs) (106, 165) and induction of various regulatory/suppressive myeloid 
cell phenotypes, for example expression of iNOS-limiting arginase (109, 166, 167). 
The overall result of these deactivating pathways is the avoidance of potentially life-threatening levels of 
inflammation and tissue damage at the expense of incomplete clearance of the infection (Figures 2 and 3). 
The situation at the tissue-specific level, however, is likely to be more complex because only a subset of 
tissues serve as privileged sites for T. cruzi persistence in the chronic phase (26).
Stage 3: The 1% and the chronic host-parasite equilibrium
In the chronic phase, blood parasitaemia is typically sub-patent and tissue parasite loads are between 0.1 
and 1% of their levels in the acute phase (4, 29). Animal imaging studies (4) and serial analysis of patient 
blood by PCR (168) show infection levels fluctuate over time, pointing to a dynamic equilibrium between 
intracellular parasite replication, antibody and effector T cell activity. The state of this equilibrium at the 
organismal level is the product of many discrete host-parasite interactions within and between multiple 
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tissues (Figure 2). Over time, these interactions can become overtly pathological and subsets of infected 
people develop a spectrum of symptomatic forms of Chagas disease, as reviewed elsewhere (169).  
Given the difficulty in sampling tissue parasites from humans, most of our knowledge on their tissue 
distribution comes from animal models. These indicate that chronic infection dynamics are shaped by the 
combination of T. cruzi strain and the hosts genetic background. It appears that the GI tract, mainly the 
large intestine and stomach, is a universal site of continual parasite persistence in mice (29, 170, 171). The 
well-studied parasite strain CL Brener is also commonly detected in the skin of BALB/c mice (38) but only 
sporadically in other sites e.g. skeletal muscle, lung, adipose. More virulent parasite strains (e.g. Brazil, 
Colombiana, Tulahuen, VFRA) and certain mice (e.g. C3H) are associated with more disseminated 
infections, including heart and skeletal muscle localisation (29, 170-176). There have been few robust data 
on the relevant cell types within any of these chronically infected tissues, but recent in vivo imaging 
analysis at single cell resolution revealed smooth muscle cells as the most frequent targets in the colon 
(176). 
A population of central memory T cells (TCM) is detectable during the chronic phase of infection, which 
may stem from a lack of parasite antigen in lymph nodes draining non-parasitized organs (104, 177). 
These TCM are maintained after benznidazole-mediated cure of chronic infection and provide protection 
against re-challenge after transfer into naïve mice (178). Homologous challenge infections, in drug-cured 
mice themselves, result in acute parasite loads less than 1% of those in primary infection controls and 
fully sterile protection is seen in around half of the animals (35). The determinants of both categories of 
protection remain to be defined, but it is likely critically dependent on the TCM population. It is likewise an 
open question whether TCM-derived effectors contribute to suppression of tissue parasite numbers during 
chronic infections, particularly in organs subject to cycles of episodic re-invasion and clearance.
The mechanisms of immune evasion sustaining the host-parasite equilibrium during perpetual chronic 
infection are not necessarily the same as those that prevent sterile clearance in the acute to chronic 
transition, which resemble a conserved host tissue-protective, anti-inflammatory programme. They are 
also harder to study, both from the parasite perspective, owing to the scarcity of T. cruzi foci in tissues, 
and from the host perspective because of the need for conditional intervention techniques that can be 
applied after acute infections have been brought under control. The essentiality of CD8+ T cells for 
continued suppression of parasite numbers in the chronic phase is reasonably clear. Parasite loads rapidly 
rebound upon treatment with anti-CD8 antibodies, almost to the level seen with pan-adaptive A
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immunosuppression using cyclophosphamide (175, 179), although depletion of CD8+ NK cells and DCs may 
contribute to the relapse in addition to CTLs. Unlike in the acute phase, experimental anti-CD4 treatment 
has no effect on chronic parasite loads (179). Nevertheless, severe reactivation of Chagas disease in HIV 
co-infected patients indicates CD4+ T cells are vital for control and the frequent presentation of 
meningoencephalitis points to a specific role in protection against invasion of the CNS (114). 
 
There are various non-exclusive hypotheses for how a small subpopulation of parasites reliably evades 
sterilisation in the face of the sustained adaptive immune pressure. However, in our view none currently 
has compelling evidence supporting a mechanistic explanation so this will remain an active area of 
investigation.
1. Antigenic diversity
African trypanosomes famously evade host immunity using a system of antigenic variation, involving 
tightly regulated mono-allelic expression and switching of variant surface glycoprotein genes (180) but 
this is not conserved in T. cruzi. The T. cruzi genome contains enormous repetitive arrays of surface 
protein genes and there is evidence that some of these gene families or sub-families are reserved for 
expression in specific life cycle stages (2, 181). Signatures of strong positive selection in surface gene 
families (182) indicate immune pressure for diversification of antigens. At the population level, 
simultaneous expression of massively diverse decoy antigens may conceivably prevent T or B cell clones 
specific to any particular epitope from reaching sufficient frequency in infected tissues and/or effector 
capacity (83, 112, 181, 183) but direct evidence for this is lacking. 
Very little is known about how variant copy expression may be controlled at the individual cell level i.e. 
amongst amastigotes and amongst trypomastigotes. Investigating this is difficult, because gene control is 
mainly post-transcriptional and suitable variant-specific monoclonal antibodies are lacking. Available 
evidence suggests that within a class of surface proteins, expression in individual parasites is not strictly 
mono-allelic. For example, trypomastigotes can co-express at least two members of the mucin (184) and 
GP85 families (183). The finding that a specific mucin-associated surface protein (MASP) peptide was only 
expressed in ~5% of parasites indicates that neither is expression totally promiscuous at the protein level 
(185). Mechanisms controlling the expression of parasite surface proteins may therefore vary between 
gene families or sub-families. T. cruzi may also regulate its antigenic repertoire expression between 
infection phases and between different host cell types. This requires much deeper analysis because A
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currently there is insufficient data to rule out clonal antigenic variation as a mechanism contributing to 
perpetual immune evasion.
2. Parasite dormancy
Many pathogens use dormancy or metabolic quiescence as an immune evasion strategy (186, 187). At the 
population level, T. cruzi amastigotes can rapidly decrease their replication rate in response to changes in 
in vitro culture conditions but this is a function of a longer G1 phase rather than exit from the cell cycle 
(188). Individual non-replicating amastigotes also occur spontaneously in vitro and are less susceptible to 
the anti-parasitic drug benznidazole (21). The frequency of 4-day replication arrested in vitro amastigotes 
has been estimated to be approximately 0.1  6 %, depending on the parasite strain (189). The in vivo 
relevance of these phenomena remains almost completely unknown and will be hard to establish 
definitively, not least because neither amastigote DNA/kDNA replication, nor differentiation to 
constitutively non-replicating trypomastigotes is synchronised (22). Nevertheless, it is reasonable to 
suspect that slowly replicating or transiently arrested intracellular parasites could have a selective 
advantage under immunological pressure and play a role in sustaining chronic infections.
3. Cytokine-mediated suppression of type 1 responses
T. cruzi may continue to benefit from the above-mentioned conserved negative-feedback mechanisms 
that damp down the acute inflammatory response. However, administration of blocking antibodies 
targeting IL-10 signalling had no discernible effect on chronic T. cruzi infections (175). This is in stark 
contrast to the well-established role of IL-10 in promoting chronicity of infections with the related 
parasite Leishmania spp. (190), which predominantly infects professional antigen-presenting cells. 
Chemical inhibition of the TGF-beta type I receptor significantly alleviated cardiac pathology and function 
in chronically infected mice, but this was not associated with any change in heart parasite loads (191). It 
should be noted that parasite loads in the chronic phase are often close to the limit of detection, which 
means that in these types of intervention experiment it is relatively clear when immunity is compromised, 
but difficult to conclusively demonstrate a significant enhancement of infection control. 
Cytokine gene expression in heart tissue from human patients with severe chronic Chagas 
cardiomyopathy remains strongly polarised to a type 1 profile (192). Type 2 cytokine (IL-4, IL-5, IL-13) 
expression is reported as undetectable (192) and while it is a feature of some animal models, this is A
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apparently not at the expense of 7:J production (170). Interestingly, helminth co-infection is associated 
with reduced control of T. cruzi in a subset of patients, potentially as a result of a modulation of the 
cytokine balance (193). Overall, cytokine-mediated suppression of anti-parasitic type 1 inflammation likely 
influences the host-parasite equilibrium and long-term disease progression, but there is little evidence 
that it explains T. cruzi chronicity.
4. Immunological exhaustion
T cell exhaustion is a feature of many infectious and non-infectious diseases that involve chronic antigen 
stimulation and this has been a recent focus of research in the Chagas disease field. Analysis of PBMCs 
from Chagas patients revealed increased frequencies of CD4+ and CD8+ T cells expressing exhaustion 
markers e.g. PD-1+, CTLA4+, TIM-3+ (194-196). Experimental studies suggest the development of 
exhaustion characteristics may be promoted by suboptimal B cell (152), IL-17A (197) or IL-10 (198) 
immune responses. Nevertheless, in chronically infected children and mice, both effector and memory 
CD8+ T cells retain cytotoxic capacity and there is little to no evidence of functional exhaustion (119, 152, 
175, 178, 199). Infection chronicity may also promote dysregulation of the Tfh and B cell compartments, 
for example, distinct phenotypes and frequencies of these have been noted between symptomatic and 
asymptomatic T. cruzi-infected individuals (200, 201). Whether these alterations reflect a process of B-cell 
exhaustion which negatively impacts parasite control remains to be further elucidated. In summary, while 
deterioration of lymphocyte functional capacity may potentially be associated with progression from 
asymptomatic to symptomatic disease states, via progressively loosened control of parasite loads, 
exhaustion does not seem to be a core reason for parasite persistence per se. 
5. Local and hyper-local immune privilege 
The realisation that long-term T. cruzi infections exhibit an unexpectedly high degree of spatio-temporal 
dynamism (4) indicates that host responses and evasion mechanisms, including those set out above, need 
to be studied more intensively at the tissue-specific level. Motile trypomastigotes probably traffic 
between tissues in both blood and lymph, but there is also evidence that a significant amount of parasite 
trafficking between tissues may occur inside SLAMF1+ myeloid cells, akin to a Trojan horse strategy (202). 
Consequently, parasites from privileged reservoir sites, such as the digestive tract, may seed other, less 
permissive sites such as the heart, resulting in episodic cycles of re-invasion and locally sterilizing host 
responses (26) (Figure 2). Tissue-specific variability in permissiveness is consistent with divergent A
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responses observed in different secondary lymphoid organs (203). Moreover, when chronically infected 
mice are immunosuppressed, the infection relapses first in the GI tract and then disseminates to other 
organs (29). Host microbiota may also play a role: its composition can be modulated by T. cruzi infection 
(204), but it is not yet known whether this in turn influences anti-parasite immunity in barrier tissues.
To keep up with the parasite, effector cells must be continually deployed to infection foci in many organs. 
There appears to be no problem with T cell homing and entry into infected tissues (205), which is 
dependent on expression of integrins including VLA-4 and LFA-1 (175, 206), and CXCR3 chemokine 
receptor signalling (207). After extravasation though, the distinct microenvironment of each organ 
potentially drives phenotypic changes to infiltrating cells and in some cases the effect may be tolerogenic 
and incompatible with local sterilisation. For example, skeletal muscle bulk CTLs recovered from early 
chronic phase mice produced less 7:J and had greatly diminished cytotoxic activity compared to splenic 
CTLs (208). Similar results have been reported for cardiac muscle compared to blood (205). Intriguingly, 
splenic CTLs adoptively transferred from one chronically infected mouse to another retained a high 7:J 
response phenotype if they migrated to spleen or lung tissue, but lost it if they migrated to skeletal 
muscle or liver (208). More recently, however, direct ex vivo analysis of parasite-specific CTLs without 
antigen re-stimulation showed cells from chronically infected skeletal muscle tissue had equal or even 
greater effector capacity (production of 7:J2 8:7L2 granzyme B) than spleen-derived cells (175). To our 
knowledge, detailed analysis of CTLs in smooth muscle has yet to be conducted.
There is thus likely to be further compartmentalisation of response and evasion dynamics at the intra-
organ level, perhaps even down to the hyper-local scale of individual infected cells microenvironments. 
For example, the muscular, neuronal and mucosal layers of the GI tract, a key site of T. cruzi persistence, 
have distinct immunological microenvironments that respond differently to Salmonella infection (209). 
Recent work has highlighted differences in the cellular composition of perivascular and parenchymal 
inflammatory infiltrates in T. cruzi-infected skeletal muscle (172, 179). Large, apparently immunologically 
invisible parasite nests even occur immediately adjacent to severely inflamed blood vessels, which led 
these authors to suggest leukocytes might fail to migrate through the parenchyma to infected cells 
because chemoattractant signalling is too weak in low parasite load settings (172). Immune evasion may 
also operate at the level of physical interaction between T cells and parasite antigen presenting cells, for 
example via manipulation of MHC class I or II expression (107, 210-212) or by parasitism of muscle cells, 
which are poor activators of :7S0 upon T. cruzi infection (76) and, in the case of skeletal muscle, do not 
normally express MHC class I (213). A
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Conclusions 
From its origins in ancient South American fauna, T. cruzi has spread to diverse mammalian orders across 
the Americas and become a widespread human pathogen. This reflects a remarkable adaptability to 
evade mammalian immune responses and maintain enzootic, zoonotic and anthroponotic transmission 
cycles. As we have set out, this involves sophisticated molecular mechanisms that allow T. cruzi to resist 
innate responses so that in the early stages of infection parasite loads are high and widely disseminated in 
blood and solid organs. The adaptive immune response, principally effected by CTLs and antibodies, is 
able to eliminate ~99% of the parasites. The infection then transitions to a permanent chronic phase in 
which parasites replicate, mainly within muscle cells in a small number of privileged tissues, in a dynamic 
equilibrium with host responses. The available evidence supports the existence of a complex set of 
molecular and cellular mediators that firstly, prevent complete sterile clearance at the acute to chronic 
transition and, secondly, ensure perpetual parasite persistence during the chronic phase. These include 
parasite-intrinsic evasion mechanisms, direct and indirect manipulation of host responses, and host-
intrinsic deactivating feedback loops. Further complexity arises from T. cruzis cycling between intra and 
extra-cellular parasite forms and its trafficking between different organs, tissues and cells, each with 
specific immunological microenvironments of variable permissiveness. 
Important advances in fundamental aspects of tissue level immunity have yet to be investigated in detail 
in the Chagas disease field, for example, defining relative contributions of tissue resident and 
inflammatory myeloid cells, innate lymphoid cell populations, tissue resident memory T cells and neuro-
immune interactions. Further progress in understanding T. cruzi-host interactions and how they shape 
Chagas disease pathogenesis is also likely to come from more intensive research at the tissue-specific and 
even single cell scale. Some key questions include: (i) Why do some infected people remain asymptomatic 
carriers while others progress to life-threatening disease states? (ii) Does active infection support 
concomitant immunity to second infections? (iii) Do drug-cured patients have protective immunity to re-
infection? (iv) Can vaccines be developed that provide sterile protection? (v) To what degree are the 
proposed mechanisms of immune evasion actually enabling parasite persistence in vivo in different 
tissues? (vi) How do host-parasite interactions promote or limit in utero transmission? The difficulties of 
answering these questions and addressing the wider challenges in Chagas disease biomedicine are great; 
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however, the massive unmet need for better treatments, prophylaxis and diagnostics requires us to 
overcome them.
Figure Legends
Figure 1. Visualisation of Trypanosoma cruzi infection foci in vivo using bioluminescent-fluorescent dual 
reporter parasites.
Figure 2. Overview of host-parasite interaction dynamics in Trypanosoma cruzi infections. Chart 
illustrates some alternative course of infection scenarios for acute and chronic phase total parasite 
burdens, feeding into potential clinical outcomes, which range from long-term non-progression to severe 
Chagas disease affecting the heart and/or gastrointestinal tract. The chronic equilibrium scenarios are the 
product of many temporally overlapping host-parasite interactions within and between the various organs 
targeted for infection by T. cruzi. Three possible non-mutually exclusive modes of persistence at the tissue 
or tissue sub-domain level are illustrated above the chart, continual persistence, dormancy/reactivation 
and episodic re-invasion.
Figure 3. Overview of the principal cellular and molecular components of the immune response to T. 
cruzi infection. Central panel shows key cell types, cytokines and effector molecules. SC, somatic cells, NK, 
Natural Killer cells, M, myeloid cells, GR, granulocytes, CD8, cytotoxic T cell, CD4, helper T cell, B, B cell, 
PC, plasma cell. Left and right panels show parasite and host factors potentially contributing to infection 
chronicity.
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